



---

## A Patent Policy in Line with Open Science and Public Benefit

Lykos Therapeutics has been working since its formation when founded as MAPS Public Benefit Corporation in 2014 to change the way mental health conditions are treated by integrating psychedelic-assisted therapies into the healthcare system. As a leader in the field, Lykos is focused on making our treatments accessible to patients while supporting the research and development of psychedelic therapies. In line with our values of openness, impact, integrity, and care, this requires balancing support for open science with creating a self-sustaining business model.

To this end, our patent policy supports the development of patentable treatments while having a philosophy of enforcement of such intellectual property in line with open science and the tenets of our public benefit. When filing patents, we intend to only do so to protect novel discoveries and not to create unreasonable barriers to either innovation or access. This position is an evolution from our policy at our origin. We believe it will enable us to support the development of potential new prescription treatments to help as many appropriate patients as possible.

We believe in the profound benefits of open science—the wide and free sharing of research, data, samples, software, ideas and results—for many reasons, including the ability to:

- Increase access to psychedelic data to spur additional research and advance potential new psychedelic treatments;
- Promote greater community support for and participation in scientific advancements;
- Help make scientific findings more broadly accessible; and
- Increase productivity and peer-review of results.

We will look to pursue and leverage patents when they align with our values and commitments and are essential to:

- Promote patient access and assistance programs;
- Protect our innovative discoveries; and
- Help build a sustainable business capable of delivering on its mission.

It is important to note that we expect to enforce patents judiciously and in alignment with our public benefit goals to promote access to approved therapies. We plan to share updates on patents we choose to pursue per [our commitment to transparency](#).